Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (Bnt162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses

References

• WHO Coronavirus (COVID-19) Dashboard. [ cited 2022 Nov 14]; Available from: https://covid19.who.int.
   Google Scholar
• COVID-19 disease in children and adolescents: scientific brief, 29 Sep 2021. [ cited 2022 Nov 14]; Available from: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Sci_Brief-Children_and_adolescents-2021.1.
   Google Scholar
• Akgün Ö, Çakmak F, Guliyeva V, et al. Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases. Rheumatology (Oxford). 2022;61(11):4482–4490. DOI:10.1093/rheumatology/keac140
   PubMed Web of Science ®Google Scholar
• Heshin-Bekenstein M, Ziv A, Toplak N, et al. Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications. Rheumatology (Oxford). 2022;61(11):keac103. DOI:10.1093/rheumatology/keac103
   PubMed Web of Science ®Google Scholar
• Crane HM, Grunfeld C, Willig JH, et al. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS. 2011;25(2):185–195. DOI:10.1097/QAD.0b013e328341f925
   PubMed Web of Science ®Google Scholar
• Haslak F, Gunalp A, Cebi MN, et al. Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: a single-center study. Int J Rheum Dis. 2022;25(3):353–363. DOI:10.1111/1756-185X.14279
   PubMed Web of Science ®Google Scholar
• Mark C, Gupta S, Punnett A, et al. Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase. Pediatr Blood Cancer. 2021;68(11):e29295. DOI:10.1002/pbc.29295
   PubMed Web of Science ®Google Scholar
• Piccini B, Pessina B, Pezzoli F, et al. COVID-19 vaccination in adolescents and young adults with type 1 diabetes: glycemic control and side effects. Pediatr Diabetes. 2022;23(4):469–472. DOI:10.1111/pedi.13326
   PubMed Web of Science ®Google Scholar
• Revon-Riviere G, Ninove L, Min V, et al. The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: a monocentric experience. Eur J Cancer. 2021;154:30–34.
   PubMed Web of Science ®Google Scholar
• Valentini D, Cotugno N, Scoppola V, et al. Safety and long-term immunogenicity of bnt162b2 vaccine in individuals with down syndrome. J Clin Med. 2022;11(3):694. DOI:10.3390/jcm11030694
   PubMed Web of Science ®Google Scholar
• Tenforde MW, Talbot HK, Trabue CH, et al. Influenza vaccine effectiveness against hospitalization in the United States, 2019–2020. J Infect Dis. 2021;224(5):813–820. DOI:10.1093/infdis/jiaa800
   PubMed Web of Science ®Google Scholar
• Allali S, Chalumeau M, Launay O, et al. Conjugate Haemophilus influenzae type b vaccines for sickle cell disease. Cochrane Database Syst Rev. 2018;8(4): CD011199. DOI:10.1002/14651858.CD011199.pub3
   PubMedGoogle Scholar
• Thomas SJ, Moreira EDJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021;385(19):1761–1773. DOI:10.1056/NEJMoa2110345
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. DOI:10.1056/NEJMoa2034577
   PubMed Web of Science ®Google Scholar
• Gargano JW, Wallace M, Hadler SC. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices — United States, June 2021. MMWR Morb Mortal Wkly Rep. [[cited 2022 Feb 7]] 2021;70(27):977–982. InternetAvailable from https://www.cdc.gov/mmwr/volumes/70/wr/mm7027e2.htm
   PubMed Web of Science ®Google Scholar
• Klein NP, Stockwell MS, Demarco M, et al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(9):352–358. DOI:10.15585/mmwr.mm7109e3
   PubMed Web of Science ®Google Scholar
• Doherty M, Schmidt-Ott R, Santos JI, et al. Vaccination of special populations: protecting the vulnerable. Vaccine. 2016;34(52):6681–6690. DOI:10.1016/j.vaccine.2016.11.015
   PubMed Web of Science ®Google Scholar
• Bergman P, Blennow O, Hansson L, et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine. 2021;74:103705.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928. DOI:10.1136/bmj.d5928
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
   PubMed Web of Science ®Google Scholar
• Shi J, Luo D, Weng H, et al. Optimally estimating the sample standard deviation from the five-number summary. Res Synth Methods. 2020;11:641–654.
   PubMed Web of Science ®Google Scholar
• Luo D, Wan X, Liu J, et al. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785–1805. DOI:10.1177/0962280216669183
   PubMed Web of Science ®Google Scholar
• Psichogiou M, Karabinis A, Poulakou G, et al. Comparative immunogenicity of BNT162b2 mRNA vaccine with natural SARS-CoV-2 Infection. Vaccines (Basel). 2021;9(9):1017. DOI:10.3390/vaccines9091017
   PubMed Web of Science ®Google Scholar
• Dimopoulou D, Spyridis N, Vartzelis G, et al. Safety and tolerability of the COVID-19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors. Arthritis Rheumatol. 2022;74(2):365–366. DOI:10.1002/art.41977
   PubMed Web of Science ®Google Scholar
• King H, Deshpande S, Woodbridge T, et al. Initial experience of the safety and tolerability of the BNT162b2 (Pfizer-Bio-N-Tech) vaccine in extremely vulnerable children aged 12–15 years. Arch Dis Child. 2022;107(2):205–207. DOI:10.1136/archdischild-2021-322655
   PubMed Web of Science ®Google Scholar
• Michos A, Filippatos F, Tatsi E-B, et al. Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis. J Cyst Fibros. 2022;21(3):e184–187. DOI:10.1016/j.jcf.2022.04.004
   PubMed Web of Science ®Google Scholar
• Haranaka M, Baber J, Ogama Y, et al. A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. Nat Commun. 2021;12(1):7105. DOI:10.1038/s41467-021-27316-2
   PubMed Web of Science ®Google Scholar
• Ab Rahman N, Lim MT, Lee FY, et al. Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: a self-controlled case series study. Vaccine. 2022;40(32):4394–4402. DOI:10.1016/j.vaccine.2022.05.075
   PubMed Web of Science ®Google Scholar
• Labib A, Rosen J, Yosipovitch G. Skin manifestations of diabetes mellitus. In: Feingold K, Anawalt B Boyce A, et al. editors. In Endotext [Internet]. South Dartmouth (MA);[cited 2022 Nov 15] 2000. Available from http://www.ncbi.nlm.nih.gov/books/NBK481900/
   Google Scholar
• Crane C, Phebus E, Ingulli E. Immunologic response of mRNA SARS-CoV-2 vaccination in adolescent kidney transplant recipients. Pediatr Nephrol. 2022;37(2):449–453.
   PubMed Web of Science ®Google Scholar
• Chantasrisawad N, Puthanakit T, Tangsathapornpong A, et al. Immunogenicity and reactogenicity of mRNA BNT162b2 COVID-19 vaccine among Thai adolescents with chronic diseases. Vaccines (Basel). 2022;10(6):10. DOI:10.3390/vaccines10060871
   Web of Science ®Google Scholar
• Levy I, Wieder-Finesod A, Litchevsky V, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clin Microbiol Infect. 2021;27(12):1851–1855. DOI:10.1016/j.cmi.2021.07.031
   PubMed Web of Science ®Google Scholar